Search Results
23 protocol(s) meet the specified criteria
100890Open  
Phase IB (Open-Label) / Phase II (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine with or without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

101274Open  
Phase I Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors likely to Express Prolactin Receptor (PRLR)

101282Open  
Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma

102310Open  
Pembrolizumab for the Treatment of Recurrent High-Grade Neuroendocrine Carcinoma

103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

104250Open  
Randomized Phase III Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

104630Open  
Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors (FIM)

106431Open  
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

43948Open  
Multi-Tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents

56630Open  
Phase II/III Trial of Neoadjuvant FOLFOX with Selective use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

83992Open  
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma

86211Open  
Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

87144Open  
Phase IB Trial of a Combination of mFOLFIRI with MEK162 in Patients with Advanced KRAS Positive Metastatic Colorectal Cancers

92314Open  
Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

93944Open  
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel plus Gemcitabine Compared with Placebo plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

94144Open  
Phase IB, Open-Label, Multicenter Study to Characterize the Safety, Tolerability, and Pharmacodynamics (PD) of PDR001 in Combination with LCL161, Everolimus (RAD001), or Panobinostat (LBH589)

95464Open  
Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations who Failed Previous Therapy

95981Open  
Phase IB Study of OMP-305B83 plus FOLFIRI in Subjects with 2nd-Line Metastatic Colorectal Cancer

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors